Mangoceuticals, Inc. (MGRX) stock
MGRXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
$0.15−0.03 (-16.22%)
Close on Nov 13, 2026Market cap $3.34MP/E –Yield –
Mangoceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Mangoceuticals's EPS for the twelve months ending Jun 30, 2026 was -$1.22. For fiscal 2025 it was -$2.17.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$2.17 | – |
| FY2024 | Dec 31, 2024 | -$4.80 | – |
| FY2023 | Dec 31, 2023 | -$8.58 | – |
| FY2022 | Dec 31, 2022 | -$2.85 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.09 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.22 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.22 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.69 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.57 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.12 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.74 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.14 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.37 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.50 | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.96 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.70 | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.10 | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.45 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.75 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.50 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.60 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.04 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?